Home › Funds › GREAT POINT PARTNERS LLC › LBRX
GREAT POINT PARTNERS LLC position in LBRX
LB PHARMACEUTICALS INC · Health Care
GREAT POINT PARTNERS LLC reported holding 317,221 shares of LBRX (LB PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$10.3M, representing 2.16% of its reported portfolio and ranking #20 among its reported holdings. GREAT POINT PARTNERS LLC has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GREAT POINT PARTNERS LLC's LBRX position evolved
GREAT POINT PARTNERS LLC first disclosed a stake in LBRX in Q1 2026 at 300,000 shares (US$7.4M). The position peaked in Q2 2026 at 317,221 shares, worth US$10.3M. Across 2 filings, GREAT POINT PARTNERS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 317,221 shares valued at US$10.3M — an increase of 17,221 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 300.00K | $7.40M | New |
| Q2 2026 | 317.22K | $10.30M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 110 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Vivo Capital, LLC 800.00K sh · $25.96M · Q2 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- HighVista Strategies LLC 211.51K sh · $6.86M · Q2 2026
More on GREAT POINT PARTNERS LLC
FAQ
How long has GREAT POINT PARTNERS LLC held LBRX?
GREAT POINT PARTNERS LLC has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is GREAT POINT PARTNERS LLC's current position in LBRX?
As of Q2 2026, GREAT POINT PARTNERS LLC holds 317.22K shares of LBRX (LB PHARMACEUTICALS INC), valued at $10.30M, representing 2.16% of its reported portfolio and ranking #20.
Has GREAT POINT PARTNERS LLC been buying or selling LBRX?
In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC increased its position in LBRX. The position peaked in Q2 2026 at 317.22K shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 110 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.